Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Premature ovarian insufficiency management

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Amenorrhoea may conceal urgent disease

Pelvic pain or bleeding with a positive pregnancy test, haemodynamic instability, severe headache with visual loss, adrenal crisis, acute mania or suicidal intent is not routine premature ovarian insufficiency care.

Action: Assess observations and pregnancy status, examine the relevant system, obtain urgent targeted tests, and use emergency pregnancy, endocrine or mental-health pathways before continuing the elective ovarian-insufficiency work-up.

Synopsis

Confirm premature ovarian insufficiency accurately, investigate likely causes, provide physiological sex-steroid replacement and contraception advice, and protect fertility, bone, cardiovascular, sexual and psychological health.

  • Suspect POI before age 40 when absent or infrequent periods coexist with vasomotor, genitourinary, sleep, mood or sexual symptoms after pregnancy and common secondary causes are considered.
  • NICE diagnosis requires compatible symptoms and elevated FSH on two blood samples taken four to six weeks apart; do not diagnose from one result or use AMH routinely.
  • Review previous ovarian surgery, chemotherapy, radiotherapy, infection, autoimmune disease and family history. For non-iatrogenic POI, offer chromosomal analysis and FMR1 premutation testing with consent and genetic counselling; age should not restrict access. Check TSH at diagnosis and screen for 21-hydroxylase antibodies when the cause is unknown; many spontaneous cases remain idiopathic after appropriate investigation.
  • Offer sex-steroid replacement with HRT or a combined hormonal contraceptive unless contraindicated and continue until at least the usual age of natural menopause.
  • Aim for physiological replacement: BMS suggests transdermal estradiol 75 to 100 micrograms daily, estradiol gel equivalent to 2 mg daily, or oral estradiol 2 mg daily, individualised to response and risk.
  • Protect an intact endometrium with proportional progestogen; a cyclic regimen is often useful when intermittent ovarian activity or pregnancy remains relevant.
  • HRT is not contraception because ovarian activity can recur unpredictably; provide a contraceptive method if pregnancy is not desired, or choose eligible combined hormonal contraception as both replacement and contraception.
  • Address fertility wishes early, arrange baseline DXA where available, assess cardiovascular risk and psychological wellbeing, and involve reproductive, menopause, genetic or endocrine specialists according to cause and goals.

    • Key red flags

    Amenorrhoea with pelvic pain, vaginal bleeding, syncope or shoulder-tip pain requires immediate pregnancy testing and urgent exclusion of ectopic pregnancy.

    Hypotension, vomiting, abdominal pain, hyponatraemia or hyperkalaemia with autoimmune features raises concern for adrenal insufficiency and needs urgent endocrine assessment.

    Severe headache, visual-field change, galactorrhoea or focal neurological findings requires assessment for pituitary or intracranial disease rather than an ovarian label alone.

    Rapid virilisation, a pelvic mass or progressive abdominal distension suggests androgen-secreting or structural disease and warrants urgent specialist assessment.

    Profound distress, self-harm thoughts, mania, psychosis or inability to stay safe requires same-day mental-health risk assessment alongside sensitive reproductive care.

    Investigation priorities

    01
    Urine or serum hCGFirst step

    Exclude pregnancy before diagnosing POI or changing hormone treatment in anyone with reproductive potential.

    Management branches

    ConfirmEstablish POI without shortcuts

    A person under 40 reports sustained menstrual disturbance with compatible symptoms.

    1. Exclude pregnancy, document hormone use and assess thyroid, prolactin, hypothalamic, structural and systemic alternatives suggested by the presentation.
    2. Obtain two elevated FSH measurements four to six weeks apart under conditions in which the result can be interpreted, avoiding routine AMH diagnosis.
    3. If results conflict, hormonal treatment obscures testing or the presentation is atypical, involve menopause or reproductive medicine expertise before assigning the diagnosis.

    Key medicines

    Transdermal estradiol for POIUse a transdermal estradiol patch delivering 75 to 100 micrograms per 24 hours, changed at the product-specific interval and titrated to physiological replacement and clinical response.Add adequate progestogen when a uterus is present; assess unexplained bleeding, hormone-sensitive cancer and thrombotic or hepatic context, and remember that estradiol does not provide contraception.
    Oral or gel estradiol for POIBMS suggests oral estradiol 2 mg once daily or an estradiol-gel regimen equivalent to 2 mg daily, adjusted for the chosen product and response.Oral oestrogen has hepatic first-pass effects; reconcile migraine, VTE risk, liver disease and adherence, and pair treatment with proportional endometrial protection.
    Open full textbook →Answer 2 questions
    Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • NICE NG23 premature ovarian insufficiency recommendations
    • BMS premature ovarian insufficiency consensus statement
    • CoSRH contraception over forty guideline amended May 2025
    • ESHRE evidence-based POI guideline

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom